Membrane Internalization Mechanisms and Design Strategies of Arginine-Rich Cell-Penetrating Peptides
Overview
Chemistry
Molecular Biology
Authors
Affiliations
Cell-penetrating peptides (CPPs) have been discovered to deliver chemical drugs, nucleic acids, and macromolecules to permeate cell membranes, creating a novel route for exogenous substances to enter cells. Up until now, various sequence structures and fundamental action mechanisms of CPPs have been established. Among them, arginine-rich peptides with unique cell penetration properties have attracted substantial scientific attention. Due to the positively charged essential amino acids of the arginine-rich peptides, they can interact with negatively charged drug molecules and cell membranes through non-covalent interaction, including electrostatic interactions. Significantly, the sequence design and the penetrating mechanisms are critical. In this brief synopsis, we summarize the transmembrane processes and mechanisms of arginine-rich peptides; and outline the relationship between the function of arginine-rich peptides and the number of arginine residues, arginine optical isomers, primary sequence, secondary and ternary structures, etc. Taking advantage of the penetration ability, biomedical applications of arginine-rich peptides have been refreshed, including drug/RNA delivery systems, biosensors, and blood-brain barrier (BBB) penetration. Understanding the membrane internalization mechanisms and design strategies of CPPs will expand their potential applications in clinical trials.
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines.
Xiao W, Jiang W, Chen Z, Huang Y, Mao J, Zheng W Signal Transduct Target Ther. 2025; 10(1):74.
PMID: 40038239 PMC: 11880366. DOI: 10.1038/s41392-024-02107-5.
A BAG-1-inhibitory peptide, GO-Pep, suppresses c-Raf activity in cancer.
Tatli O, Cebi E, Turk M, Dingiloglu B, Sezan A, Basturk E Commun Biol. 2025; 8(1):336.
PMID: 40021821 PMC: 11871328. DOI: 10.1038/s42003-024-07419-4.
Applications of cell penetrating peptide-based drug delivery system in immunotherapy.
Du J, Zhang R, Jiang S, Xiao S, Liu Y, Niu Y Front Immunol. 2025; 16:1540192.
PMID: 39911386 PMC: 11794548. DOI: 10.3389/fimmu.2025.1540192.
Emerging Nanoparticle-Based Diagnostics and Therapeutics for Cancer: Innovations and Challenges.
Puttasiddaiah R, Basavegowda N, Lakshmanagowda N, Raghavendra V, Sagar N, Sridhar K Pharmaceutics. 2025; 17(1).
PMID: 39861718 PMC: 11768644. DOI: 10.3390/pharmaceutics17010070.
Ramasundaram M, Sohn H, Madhavan T Front Artif Intell. 2025; 7():1497307.
PMID: 39839972 PMC: 11747587. DOI: 10.3389/frai.2024.1497307.